


J&J  
withMe

Once a decision has been made to  
prescribe a Johnson & Johnson medicine

**We can help make it  
simple for you to help  
your patients**



**J&J withMe is a suite of access, affordability, and  
treatment support resources for your patients  
prescribed J&J medicines**



**Access Support** to help navigate payer processes  
by verifying insurance coverage and providing  
reimbursement information.



**Affordability Support** to help your patients start and  
stay on the J&J medicine you prescribe  
by providing affordability options that may be available.



**Treatment Support** including PAH Companion withMe,  
to help your patients get informed and stay on  
prescribed J&J medicines.




**If you have questions, call a  
J&J withMe Care Coordinator at 866-228-3546,  
Monday-Friday, 8 AM-8 PM ET.  
Multilingual phone support available.**

The patient support and resources provided by J&J withMe and  
PAH Companion withMe are not intended to provide medical advice,  
replace a treatment plan from the patient's doctor or nurse, provide case  
management services, or serve as a reason to prescribe a J&J medicine.



# Complete Treatment Journey Support

Choose from a suite of support resources



Please read the full Prescribing Information, including **BOXED WARNING**, and Medication Guide for OPSUMIT® available at [JNJwithMe.com](https://JNJwithMe.com). Provide the Medication Guide to your patients and encourage discussion.

Please read the full Prescribing Information, including **BOXED WARNING**, and Medication Guide for OPSYNVI® available at [JNJwithMe.com](https://JNJwithMe.com). Provide the Medication Guide to your patients and encourage discussion.

Please see the full Prescribing Information and Patient Product Information for UPTRAVI® available at [JNJwithMe.com](https://JNJwithMe.com). Provide the Patient Product Information to your patients and encourage discussion.

J&J

# withMe PAH Companion withMe

PAH Companion withMe\* provides patients with free, one-on-one support from a PAH-trained professional to guide them on their journey.

## The program offers:

- **Tools and Resources** – May help patients stay on therapy longer.<sup>††</sup>
- **High Satisfaction** – 94% of patients would recommend the program to others.<sup>2</sup>
- **Active Engagement** – 10,000+ patients have engaged in PAH Companion withMe.<sup>3</sup>
- **Bilingual Support** – English and Spanish.

## May help patients stay on therapy longer<sup>††</sup>

**80% of patients** who engaged in PAH Companion withMe and the UPTRAVI® Titration Education Program were **still on therapy 120 days after** therapy initiation **compared to 59% of patients** who did not engage in either program.<sup>†§</sup>

**Once your patients enroll in PAH Companion withMe, they will have access to:**




### Dedicated Personal Support

- One-on-one conversations with a dedicated PAH Companion



### PAH Education

- Receive education about medication information
- Use self-guided resources for living with PAH



### Connection to Online PAH Community

- Access peer support groups
- Receive current PAH information and resources
- Utilize digital tools to connect to others while monitoring their health

Visit <https://www.pahcompanion.com/> to learn more about the support available to your patients.

\*PAH Companion withMe is only for patients on certain PAH medicines by J&J and requires a completed patient authorization form to enroll.

<sup>†</sup>Based on the proportion of patients who engaged in the program versus those who did not engage in the program and were still on therapy 120 days after treatment initiation. Analysis of J&J HUB data derived from specialty pharmacy transactions from 4/1/23 – 3/31/24.

<sup>†</sup>Based on J&J HUB and specialty pharmacy transactions data from 4/1/23 – 3/31/24.

<sup>§</sup>A statistical analysis to compare the two groups was not conducted.



For Your Patients Prescribed UPTRAVI®

## UPTRAVI® Titration Education Program

After you, as the treating healthcare professional (HCP), have made the decision to prescribe UPTRAVI® (selexipag), **you may choose for your patient to receive nurse-supported titration education as they start therapy.**



For patients to receive this service, **you must check the box in section 4 (choose virtual or in-home visits) of the Enrollment and Prescription Form** to opt in to the UPTRAVI® Titration Education Program.

Within 48 hours of your patient's receipt of their first UPTRAVI® shipment, a Specialty Pharmacy Nurse can have an interaction with your patient.

**80%** of new patients  
utilize the program<sup>4</sup>

**Patients engaged in the program are more likely to stay on therapy.<sup>1†</sup>**

### Program Updates

#### Virtual or in-home

**The program is delivered to patients virtually (by video or phone) or in-home,** depending on the patient or provider preference captured on the Enrollment and Prescription Form or communicated by patient or provider.

#### Educational visits aligned with patient's UPTRAVI® dose titration schedule

The program will take place during a series of interactions aligned with the UPTRAVI® dose titration schedule. The program will conclude after 5 interactions. If a patient requires additional titration education beyond 5 interactions, the patient may receive a limited number of additional interactions.

### Reminder of Program Features

During these visits with your patient, the nurse can:

- EDUCATE** the patient on what to expect as they start therapy with UPTRAVI®
- ENSURE** the patient's understanding of reaching their personal dose
- EDUCATE** the patient to help address potential misconceptions about UPTRAVI® dosing
- PROVIDE** the patient and/or their caregiver with recommendations on when to call their HCP

### May help patients stay on therapy longer<sup>1†</sup>

**80% of patients** who engaged in PAH Companion withMe and the UPTRAVI® Titration Education Program were **still on therapy 120 days after therapy initiation compared to 59% of patients** who did not engage in either program.<sup>4§</sup>

<sup>†</sup>Based on the proportion of patients who engaged in the program versus those who did not engage in the program and were still on therapy 120 days after treatment initiation. Analysis of J&J HUB data derived from specialty pharmacy transactions from 4/1/23 – 3/31/24.

<sup>‡</sup>Based on J&J HUB and specialty pharmacy transactions data from 4/1/23 – 3/31/24.

<sup>§</sup>A statistical analysis to compare the two groups was not conducted.

The information provided is educational in nature and not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe.

**Please see the full Prescribing Information and Patient Product Information for UPTRAVI® available at [JNJwithMe.com](https://www.JNJwithMe.com). Provide the Patient Product Information to your patients and encourage discussion.**

# J&J withMe

*“I never knew companies had programs like this. Even just chatting really makes me feel heard.”*

— A person living with PAH

Visit <https://www.pahcompanion.com/pah-companion> to hear from Tanya and Stephanie, two of our PAH Companions.

#### REFERENCES:

1. Data on File. Actelion Pharmaceuticals US, Inc. J&J HUB and specialty pharmacy transaction data. 4/1/23 – 3/31/24.
2. Data on file. Actelion Pharmaceuticals US, Inc. Janssen PAH Q2 QBR 2022 Final. April 2023.
3. Data on file. Actelion Pharmaceuticals US, Inc. Janssen Commercial Strategy and Operations Team. September 2023.
4. Data on file. Actelion Pharmaceuticals US, Inc.